UnitedHealth (UNH) Has Strong 3Q & Pfizer (PFE) Nears Lows As Vaccine Demand Falls

Adolf Goebbels
Published on Oct 23, 2023
UBS upgraded UnitedHealth (UNH) to buy from neutral. The analyst notes that UNH’s “strong” 3Q is a “clearing event that should pave the way for improved valuation.” UBS raised UNH’s price target to $640 from $520. Jenny Horne discusses this along with Pfizer (PFE) which cut its full-year guidance as demand for Covid-19 vaccines fall. PFE’s shares are near a 52-week low. Tune in to find out more about the stock market today.

#pfizer #stocks #investing #unitedhealth #trading #healthcare #vaccine #stockmarket #wallstreet #money #finance #businessnews #news

Add to

Please Sign In or Create Account to use this feature!

Flag Video

Please Sign In or Create Account to use this feature!

Rate video

Please Sign In or Create Account to use this feature!

Rate video

Please Sign In or Create Account to use this feature!

DISCLAIMER

The content presented in this stream and/or video may be satirical in nature for entertainment purposes. It may contain realistic scenarios that may include themes of racism, anti-semitism, anti-LGBT sentiment and even elements such as death threats, all purely in the context of parody. In addition, this content may depict or refer to acts of violence in a satirical manner. Shock factor is a common and deliberate element used in these displays to emphasise the satirical message. By continuing to view this content, you acknowledge that you understand the satirical nature of this content, including the depiction of violence and the use of shock factor, and agree that you will not use or interpret this content outside of its intended context. Please remember that humour and satire are complex; they are not intended to belittle or demean, but to engage and challenge social norms through exaggeration. If you have any concerns about content, please feel free to engage in constructive dialogue or report issues to GTV staff.